Human Vaccines & Immunotherapeutics最新文献_第3页

Epidemic patterns of the different influenza virus types and subtypes/lineages for 10 years in Chongqing, China, 2010-2019. 2010-2019 年中国重庆 10 年间不同流感病毒类型和亚型/系谱的流行模式。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-06-07 DOI: 10.1080/21645515.2024.2363076

Xiaoqing Fu, Jiang Long, Yu Xiong, Zhifeng Li, Jule Yang, Dechao Tian, Zhourong Li, Shuang Yang, Li Qi

{"title":"Epidemic patterns of the different influenza virus types and subtypes/lineages for 10 years in Chongqing, China, 2010-2019.","authors":"Xiaoqing Fu, Jiang Long, Yu Xiong, Zhifeng Li, Jule Yang, Dechao Tian, Zhourong Li, Shuang Yang, Li Qi","doi":"10.1080/21645515.2024.2363076","DOIUrl":"10.1080/21645515.2024.2363076","url":null,"abstract":"To optimize seasonal influenza control and prevention programs in regions with potentially complicated seasonal patterns. Descriptive epidemiology was used to analyze the etiology of influenza, and chi-square tests were used to compare the epidemic patterns among different influenza virus types and subtypes/lineages. From January 2010 to December 2019, a total of 63,626 ILI cases were reported in Chongqing and 14,136 (22.22%) were laboratory-confirmed influenza cases. The proportions of specimens positive for influenza A and influenza B were 13.32% (8,478/63,626) and 8.86% (5,639/63,626), respectively. The proportion of positive specimens for influenza A reached the highest in winter (23.33%), while the proportion of positive specimens for influenza B reached the highest in spring (11.88%). Children aged 5-14 years old had the highest proportion of positive specimens for influenza. The influenza virus types/subtypes positive was significantly different by seasons and age groups (P<.001), but not by gender (p = .436). The vaccine strains were matched to the circulating influenza virus strains in all other years except for 2018 (vaccine strain was B/Colorado/06/2017; circulating strain was B/Yamagata). The study showed significant variations in epidemic patterns, including seasonal epidemic period and age distributions, among different influenza types, subtypes/lineages in Chongqing. Influenza vaccines matched to the circulating influenza virus strain in nine of the ten years. To prevent and mitigate the influenza outbreaks in this area, high risk population, especially children aged 5-14 years, are encouraged to get vaccinated against influenza before the epidemic seasons.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis. 细胞疫苗作为癌症疗法的效用：系统回顾和荟萃分析。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-27 DOI: 10.1080/21645515.2024.2323256

Ankur Tiwari, Karl Alcover, Elizabeth Carpenter, Katryna Thomas, Julia Krum, Alexander Nissen, Spencer Van Decar, Todd Smolinsky, Franklin Valdera, Timothy Vreeland, Markus Lacher, Giuseppe Del Priore, William Williams, Alexander Stojadinovic, George Peoples, Guy Clifton

{"title":"Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis.","authors":"Ankur Tiwari, Karl Alcover, Elizabeth Carpenter, Katryna Thomas, Julia Krum, Alexander Nissen, Spencer Van Decar, Todd Smolinsky, Franklin Valdera, Timothy Vreeland, Markus Lacher, Giuseppe Del Priore, William Williams, Alexander Stojadinovic, George Peoples, Guy Clifton","doi":"10.1080/21645515.2024.2323256","DOIUrl":"10.1080/21645515.2024.2323256","url":null,"abstract":"Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response against tumor antigens. The primary objective of this study is to perform a systematic literature review with an embedded meta-analysis of all published Phase 2 and 3 clinical trials of cell-based cancer vaccines in human subjects. The secondary objective of this study is to review trials demonstrating biological activity of cell-based cancer vaccines that could uncover additional hypotheses, which could be used in the design of future studies. We performed the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The final review included 36 studies - 16 single-arm studies, and 20 controlled trials. Our systematic review of the existing literature revealed largely negative trials and our meta-analysis did not show evidence of clinical benefit from cell-based cancer-vaccines. However, as we looked beyond the stringent inclusion criteria of our systematic review, we identified significant examples of biological activity of cell-based cancer vaccines that are worth highlighting. In conclusion, the existing literature on cell-based cancer vaccines is highly variable in terms of cancer type, vaccine therapies and the clinical setting with no overall statistically significant clinical benefit, but there are individual successes that represent the promise of this approach. As cell-based vaccine technology continues to evolve, future studies can perhaps fulfill the potential that this exciting field of anti-cancer therapy holds.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020). 西班牙与肛门和阴茎肿瘤相关的住院负担（2016-2020 年）。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-04-01 DOI: 10.1080/21645515.2024.2334001

Victor Fernandez-Alonso, Ruth Gil-Prieto, Maria Amado-Anton-Pacheco, Valentín Hernández-Barrera, Ángel Gil-De-Miguel

{"title":"Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020).","authors":"Victor Fernandez-Alonso, Ruth Gil-Prieto, Maria Amado-Anton-Pacheco, Valentín Hernández-Barrera, Ángel Gil-De-Miguel","doi":"10.1080/21645515.2024.2334001","DOIUrl":"10.1080/21645515.2024.2334001","url":null,"abstract":"In 2020, there were approximately 50,865 anal cancer cases and 36,068 penile cancer cases worldwide. HPV is considered the main causal agent for the development of anal cancer and one of the causal agents responsible for the development of penile cancer. The aim of this epidemiological, descriptive, retrospective study was to describe the burden of hospitalization associated with anal neoplasms in men and women and with penis neoplasms in men in Spain from 2016 to 2020. The National Hospital Data Surveillance System of the Ministry of Health, Conjunto Mínimo Básico de Datos, provided the discharge information used in this observational retrospective analysis. A total of 3,542 hospitalizations due to anal cancer and 4,270 hospitalizations due to penile cancer were found; For anal cancer, 57.4% of the hospitalizations occurred in men, and these hospitalizations were also associated with significantly younger mean age, longer hospital stays and greater costs than those in women. HIV was diagnosed in 11.19% of the patients with anal cancer and 1.74% of the patients with penile cancer. The hospitalization rate was 2.07 for men and 1.45 for women per 100,000 in anal cancer and of 4.38 per 100,000 men in penile cancer. The mortality rate was 0.21 for men and 0.12 for women per 100,000 in anal cancer and 0.31 per 100.000 men in penile cancer and the case-fatality rate was 10.07% in men and 8,26% in women for anal cancer and 7.04% in penile cancer. HIV diagnosis significantly increased the cost of hospitalization. For all the studied diagnoses, the median length of hospital stays and hospitalization cost increased with age. Our study offers relevant data on the burden of hospitalization for anal and penile cancer in Spain. This information can be useful for future assessment on the impact of preventive measures, such as screening or vaccination in Spain.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022. 乳腺癌免疫疗法知识图谱：2013年至2022年的文献计量分析。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-04-02 DOI: 10.1080/21645515.2024.2335728

Fanli Qu, Guanwen Wang, Ping Wen, Xiaoyu Liu, Xiaohua Zeng

{"title":"Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022.","authors":"Fanli Qu, Guanwen Wang, Ping Wen, Xiaoyu Liu, Xiaohua Zeng","doi":"10.1080/21645515.2024.2335728","DOIUrl":"10.1080/21645515.2024.2335728","url":null,"abstract":"Breast cancer is the leading cause of cancer-related death among women globally. Immunotherapy has emerged as a major milestone in contemporary oncology. This study aims to conduct a bibliometric analysis in the field of immunotherapy for breast cancer, providing a comprehensive overview of the current research status, identifying trends and hotspots in research topics. We searched and retrieved data from the Web of Science Core Collection, and performed a bibliometric analysis of publications on immunotherapy for breast cancer from 2013 to 2022. Current status and hotspots were evaluated by co-occurrence analysis using VOSviewer. Evolution and bursts of knowledge base were assessed by co-citation analysis using CiteSpace. Thematic evolution by bibliometrix package was used to discover keywords trends. The attribution and collaboration of countries/regions, institutions and authors were also explored. A total of 7,975 publications were included. In co-occurrence analysis of keywords, 6 major clusters were revealed: tumor microenvironment, prognosis biomarker, immune checkpoints, novel drug delivery methods, immune cells and therapeutic approaches. The top three most frequently mentioned keywords were tumor microenvironment, triple-negative breast cancer, and programmed cell death ligand 1. The most productive country, institution and author were the USA (2926 publications), the University of Texas MD Anderson Cancer Center (219 publications), and Sherene Loi (28 publications), respectively. There has been a rapid growth in studies on immunotherapy for breast cancer worldwide. This research area has gained increasing attention from different countries and institutions. With the rising incidence of breast cancer, immunotherapy represents a research field of significant clinical value and potential.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10989689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis. 抗PD-1/PDL-1和抗CTLA-4疗法中的免疫调节和肿瘤微环境对癌症免疫逃避的影响：文献计量分析。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-28 DOI: 10.1080/21645515.2024.2318815

Yi Huang, Zhijian Chen, Gang Shen, Shuogui Fang, Junjiong Zheng, Zepai Chi, Yuanfeng Zhang, Yitong Zou, Qinghua Gan, Chengxiao Liao, Yuhui Yao, Jianqiu Kong, Xinxiang Fan

{"title":"Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.","authors":"Yi Huang, Zhijian Chen, Gang Shen, Shuogui Fang, Junjiong Zheng, Zepai Chi, Yuanfeng Zhang, Yitong Zou, Qinghua Gan, Chengxiao Liao, Yuhui Yao, Jianqiu Kong, Xinxiang Fan","doi":"10.1080/21645515.2024.2318815","DOIUrl":"10.1080/21645515.2024.2318815","url":null,"abstract":"This study aims to conduct a bibliometric analysis, employing visualization tools to examine literature pertaining to tumor immune evasion related to anti-CTLA-4 and anti-PD-1/PD-L1 therapy from 1999 to 2022. A special emphasis is placed on the interplay between tumor microenvironment, signaling pathways, immune cells and immune evasion, with data sourced from the Web of Science core collection (WoSCC). Advanced tools, including VOSviewer, Citespace, and Scimago Graphica, were utilized to analyze various parameters, such as co-authorship/co-citation patterns, regional contributions, journal preferences, keyword co-occurrences, and significant citation bursts. Out of 4778 publications reviewed, there was a marked increase in research focusing on immune evasion, with bladder cancer being notably prominent. Geographically, China, the USA, and Japan were the leading contributors. Prestigious institutions like MD Anderson Cancer Center, Harvard Medical School, Fudan University, and Sun Yat Sen University emerged as major players. Renowned journals in this domain included Frontiers in Immunology, Cancers, and Frontiers in Oncology. Ehen LP and Wang W were identified as prolific authors on this topic, while Topalian SL stood out as one of the most cited. Research current situation is notably pivoting toward challenges like immunotherapy resistance and the intricate signaling pathways driving drug resistance. This bibliometric study seeks to provide a comprehensive overview of past and current research trends, emphasizing the potential role of tumor microenvironment, signaling pathways and immune cells in the context of immune checkpoint inhibitors (ICIs) and tumor immune evasion.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Herpes zoster in older adults: Impact on carbon footprint in the United States. 老年人带状疱疹：对美国碳足迹的影响。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-05-03 DOI: 10.1080/21645515.2024.2335722

Desmond Curran, Jacopo Bitetti, Imogen Catterall, Stephen Wincott

{"title":"Herpes zoster in older adults: Impact on carbon footprint in the United States.","authors":"Desmond Curran, Jacopo Bitetti, Imogen Catterall, Stephen Wincott","doi":"10.1080/21645515.2024.2335722","DOIUrl":"10.1080/21645515.2024.2335722","url":null,"abstract":"We provide estimates for (I) annual herpes zoster (HZ) cases, (II) carbon costs related to healthcare utilization, and (III) annual carbon emissions due to HZ among ≥50 years of age (YOA) United States (US) population. We estimated the annual number of HZ cases in the US based on available incidence data and demographic data of individuals ≥50 YOA. Both the healthcare resource utilization (HCRU) associated with HZ cases and the unit carbon dioxide equivalent (i.e. CO2e) costs associated with each type of HCRU in the US were estimated based on literature and studies available online. The carbon footprint associated with HZ annually among US adults ≥50 YOA was estimated by multiplying the unit carbon estimates by the HCRU. In the US population aged ≥50 YOA in 2020 (i.e. approximately 118 million), approximately 1.1 million cases of HZ occur annually assuming no vaccination. Based on 2 sources of HCRU the average kgCO2e per HZ patient ranged from 61.0 to 97.6 kgCO2e, with values by age group ranging from 40.9 kgCO2e in patients aged 50-59 to 195.9 kgCO2e in patients ≥80 YOA. The total annual HZ associated carbon ranged between 67,000 and 107,000 tons of CO2e in the US population aged ≥50 YOA. The impact of HZ on carbon footprint in the US results in considerable greenhouse gas (GHG)emissions. Assuming no vaccination, the burden of HZ is projected to rise over the coming years with the aging populations consequently worsening its impact on GHG emissions. (Figure 1).","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand. 泰国春武里府各年龄组水痘带状疱疹病毒抗体的血清流行率（后 COVID-19 大流行时期）。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-25 DOI: 10.1080/21645515.2024.2367283

Thanunrat Thongmee, Jira Chansaenroj, Sirapa Klinfueng, Ratchadawan Aeemjinda, Nasamon Wanlapakorn, Yong Poovorawan

{"title":"Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand.","authors":"Thanunrat Thongmee, Jira Chansaenroj, Sirapa Klinfueng, Ratchadawan Aeemjinda, Nasamon Wanlapakorn, Yong Poovorawan","doi":"10.1080/21645515.2024.2367283","DOIUrl":"10.1080/21645515.2024.2367283","url":null,"abstract":"As of 2024, Thailand has not incorporated the varicella-zoster virus (VZV) vaccine into the Expanded Program on Immunization (EPI). This study aimed to evaluate VZV seroprevalence across all age groups in Chonburi Province, Thailand, during the post-COVID-19 era, and to support the development of a vaccination plan against VZV. A total of 950 participants were enrolled from October 2022 to January 2023. VZV antibody levels were measured using ELISA kits (EUROIMMUN, Lübeck, Germany), with seropositivity set at ≥110 IU/L. The overall VZV seropositivity rate was 64.8%, similar to rates in 1994 and 2014. However, seropositivity rates for the 5-9, 10-14, and 15-19 age groups were significantly higher in the 1994 study, and for the 10-14 and 15-19 age groups in the 2014 study, indicating a declining trend among young Thai individuals. The seropositivity rate increased with age, with a seroprevalence exceeding 80% in individuals aged 30 years and older. Our study found a significant association between the history of varicella and seropositivity. Thus, a positive history may indicate immunity. In conclusion, a significant portion of Thai adolescents are still vulnerable to varicella, highlighting the crucial role of vaccination in averting serious illness.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11275523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-16 DOI: 10.1080/21645515.2024.2379689

引用次数: 0

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014. 2010-2014 年阿根廷 284 株引起侵袭性脑膜炎球菌病的奈瑟氏脑膜炎球菌分离株的遗传特征和估计 4CMenB 疫苗菌株覆盖率。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-22 DOI: 10.1080/21645515.2024.2378537

Adriana Efron, Alessandro Brozzi, Alessia Biolchi, Margherita Bodini, Maria Giuliani, Silvia Guidotti, Federico Lorenzo, María Alicia Moscoloni, Alessandro Muzzi, Florencia Nocita, Mariagrazia Pizza, Rino Rappuoli, Sara Tomei, Gabriela Vidal, Carla Vizzotti, Josefina Campos, Cecilia Sorhouet Pereira

{"title":"Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014.","authors":"Adriana Efron, Alessandro Brozzi, Alessia Biolchi, Margherita Bodini, Maria Giuliani, Silvia Guidotti, Federico Lorenzo, María Alicia Moscoloni, Alessandro Muzzi, Florencia Nocita, Mariagrazia Pizza, Rino Rappuoli, Sara Tomei, Gabriela Vidal, Carla Vizzotti, Josefina Campos, Cecilia Sorhouet Pereira","doi":"10.1080/21645515.2024.2378537","DOIUrl":"https://doi.org/10.1080/21645515.2024.2378537","url":null,"abstract":"Meningococcal (Neisseria meningitidis) serogroup B (MenB) strain antigens are diverse and a limited number of strains can be evaluated using the human serum bactericidal antibody (hSBA) assay. The genetic Meningococcal Antigen Typing System (gMATS) was developed to predict the likelihood of coverage for large numbers of isolates by the 4CMenB vaccine, which includes antigens Neisseria adhesin A (NadA), Neisserial Heparin-Binding Antigen (NHBA), factor H-binding protein (fHbp), and Porin A (PorA). In this study, we characterized by whole-genome analyses 284 invasive MenB isolates collected from 2010 to 2014 by the Argentinian National Laboratories Network (52-61 isolates per year). Strain coverage was estimated by gMATS on all isolates and by hSBA assay on 74 randomly selected isolates, representative of the whole panel. The four most common clonal complexes (CCs), accounting for 81.3% of isolates, were CC-865 (75 isolates, 26.4%), CC-32 (59, 20.8%), CC-35 (59, 20.8%), and CC-41/44 (38, 13.4%). Vaccine antigen genotyping showed diversity. The most prevalent variants/peptides were fHbp variant 2, NHBA peptides 24, 21, and 2, and PorA variable region 2 profiles 16-36 and 14. The nadA gene was present in 66 (23.2%) isolates. Estimated strain coverage by hSBA assay showed 78.4% of isolates were killed by pooled adolescent sera, and 51.4% and 64.9% (based on two different thresholds) were killed by pooled infant sera. Estimated coverage by gMATS (61.3%; prediction interval: 55.5%, 66.7%) was consistent with the infant hSBA assay results. Continued genomic surveillance is needed to evaluate the persistence of major MenB CCs in Argentina.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy. 探索接受 PD-1 抑制剂免疫疗法的晚期胰腺癌患者的生存预后因素。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-23 DOI: 10.1080/21645515.2024.2376429

Yue Ma, Shiyun Chen, Guanghai Dai

{"title":"Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy.","authors":"Yue Ma, Shiyun Chen, Guanghai Dai","doi":"10.1080/21645515.2024.2376429","DOIUrl":"10.1080/21645515.2024.2376429","url":null,"abstract":"Immunotherapy, led by programmed cell death protein-1 (PD-1) inhibitors, has emerged as a prominent antitumor therapy, yet prognostic challenges persist in pancreatic cancer (PC). This retrospective, single-center study evaluated prognostic factors in advanced PC patients treated with PD-1 inhibitors at the PLA General Hospital's Oncology Department from 2015-2022. With ethics approval by the Ethics Committee of the General Hospital of the People's Liberation Army (S2021-228-03), we analyzed 126 patients using Kaplan-Meier and Cox models. p < .05 was considered a statistically significant difference. Median overall survival (mOS) and progression-free survival (mPFS) were 12.1 and 4.6 months, respectively. Significant mOS predictors were surgery history (44.2 months vs. 10 months, *p = .022), absence of liver metastases (44.2 months vs. 6.4 months, *p = .034), and baseline CA19-9 ≤ 216.15 U/ml (18.5 months vs. 9.2 months, *p = .049). For mPFS, histologic differentiation (5.5 months vs. 3.2 months, *p = .022) and first-line PD-1 inhibitor use (5.1 months vs. 1.5 months, ***p = .001) were key. Subgroup analyses highlighted early progression in low histologic differentiation and earlier death without surgery. History of surgery, absence of liver metastases, baseline CA19-9 level, and histologic intermediate/high differentiation may predict PD-1 inhibitor efficacy in advanced PC, pending validation in prospective trials.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0